Details for Patent: 5,232,925

Title:	Compounds
Abstract:	Compounds of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.
Inventor(s):	Hindley; Richard M. (Epsom, GB2)
Assignee:	Beecham Group p.l.c. (Brentford, GB2)
Filing Date:	Jan 15, 1991
Application Number:	07/641,474
Claims:	1. A method for the treatment and/or prophylaxis of hypertension in a human or non-human mammal, which comprises administering to said human or non-human mammal in need thereof, an effective, non-toxic amount of a compound of formula (I): ##STR93## or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein A.sup.1 represents a substituted or unsubstituted, single ring aromatic heterocyclyl group having 4 to 7 ring atoms and comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen, the substituents for the heterocyclyl group being up to 4 substituents selected from the group consisting of: C.sub.1-12 -alkyl, C.sub.1-12 -alkoxy, aryl and halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted; R.sup.1 represents a hydrogen atom, a C.sub.1-12 -alkyl group, a C.sub.1-12 alkylcarbonyl group, an aryl-C.sub.1-12 -alkyl group the aryl moiety being substituted or unsubstituted, or a substituted or unsubstituted aryl group; any aryl group being phenyl or naphthyl optionally substituted with up to five groups selected from halogen, C.sub.1-12 -alkyl, phenyl, C.sub.1-12 alkoxy, halo-C.sub.1-12 -alkyl, hydroxy, amino, nitro, carboxy, C.sub.1-12 -alkoxycarbonyl, C.sub.1-12 -alkoxycarbonyl-C.sub.1-12 -alkyl, C.sub.1-12 -alkylcarbonyloxy, or a C.sub.1-12 -alkylcarbonyl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having three optional substitutents which may be selected from halogen, substituted or unsubstituted C.sub.1-12 -alkyl or C.sub.1-12 -alkoxy; substituents for the alkyl group being selected from the groups consisting of halogen, C.sub.1-12 -alkyl, phenyl, C.sub.1-12 -alkoxy, halo-C.sub.1-12 -alkyl, hydroxy, amino, nitro, carboxy, C.sub.1-12 -alkoxycarbonyl, C.sub.1-12 -alkoxycarbonyl-C.sub.1-12 -alkyl, C.sub.1-12 -alkylcarbonyloxy, or C.sub.1-12 -alkylcarbonyl; and n represents an integer in the range of from 2 to 6. 2. A method according to claim 1, wherein A.sup.1 in the compound of formula (I) represents a substituted or unsubstituted, single or fused ring aromatic heterocyclyl group comprising up to 4 hetero atoms in the ring selected from oxygen, sulphur or nitrogen. 3. A method according to claim 1, wherein A.sup.1 in the compound of formula (I) represents a moiety of formula (a), (b) or (c): ##STR94## wherein: R.sup.4 and R.sup.5 each independently represents a hydrogen atom, an alkyl group or a substituted or unsubstituted aryl group or when R.sup.4 and R.sup.5 are each attached to a carbon atom, then R.sup.4 and R.sup.5 together with the carbon atoms to which they are attached form a benzene ring wherein each carbon atom represented by R.sup.4 and R.sup.5 together may be substituted or unsubstituted; and in the moiety of formula (a) X represents oxygen or sulphur. 4. A method according to claim 3, wherein R.sup.4 and R.sup.5 in (a), (b) or (c) each independently represent hydrogen, alkyl or a substituted or unsubstituted phenyl group. 5. A method according to claim 3, wherein R.sup.4 and R.sup.5 in (a), (b) or (c) together represent a moiety of formula (d): ##STR95## wherein R.sup.6 and R.sup.7 each independently represent hydrogen, halogen, substituted or unsubstituted alkyl or alkoxy. 6. A method according to claim 5, wherein R.sup.6 and R.sup.7 in (d) each represent hydrogen. 7. A method according to claim 1, wherein A.sup.2 in the compound of formula (I) represents a moiety of formula (e): ##STR96## wherein R.sup.8 and R.sup.9 each independently represent hydrogen, halogen, substituted or unsubstituted alkyl or alkoxy. 8. A method according to claim 7, wherein R.sup.8 and R.sup.9 in (e) each represent hydrogen. 9. A method according to claim 1, of formula (II): ##STR97## or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3 and n are as defined in relation to formula (I) in claim 1 and R.sup.8 and R.sup.9 are as defined in relation to formula (e) in claim 7. 10. A method according to claim 1, wherein n in the compound of formula (I) represents an integer 2 or 3. 11. A method according to claim 1, wherein R.sup.1 in the compound of formula (I) represents a methyl group. 12. A method according to claim 1 which comprises the administration of a compound selected from the group consisting of: 5-(4-[2-(N-methyl-N-(2-benzothiazoyl)amino)ethoxy]benzyl)-2,4-thiazolidined ione; 5-(4-[2-(N-methyl-N-(2-benzothiazolyl)amino)ethoxy]benzylidene)-2,4-thiazol idinedione; 5-(4-[2-(N-methyl-N-(2-benzoxazolyl)amino)ethoxy]benzyl)-2,4-thiazolidinedi one; 5-(4-[2-(N-methyl-N-(2-benzoxazolyl)amino)ethoxy]benzylidene)-2,4-thiazolid inedione; 5-(4-[2-(N-methyl-N-(2-pyrimidinyl)amino)ethoxy]benzyl)-2,4-thiazolidinedio ne; 5-(4-[2-(N-methyl-N-(2-pyrimidinyl)amino)ethoxy]benzylidene)-2,4-thiazolidi nedione; 5-(4-(2-(N-methyl-N-[2-(4,5-dimethylthiazolyl)]amino)ethoxy]benzyl)-2,4-thi azolidinedione; 5-(4-[2-(N-methyl-N-[2-(4,5-dimethylthiazolyl)]amino)ethoxy]benzylidene)-2, 4-thiazolidinedione; 5-(4-[2-(N-methyl-N-(2-thiazolyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione 5-(4-[2-(N-methyl-N-(2-thiazolyl)amino)ethoxy]benzylidene)-2,4-thiazolidine dione; 5-[4-(2-(N-methyl-N-(2-(4-phenylthiazolyl))amino)ethoxy)benzyl]-2,4-thiazol idinedione; 5-(4-[2-(N-methyl-N-(2-(4-phenylthiazolyl))amino)ethoxy]benzylidene)-2,4-th iazolidinedione; 5-(4-[2-(N-methyl-N-[2-(4-phenyl-5-methylthiazolyl)]amino)ethoxy]benzyl)-2, 4-thiazolidinedione; 5-(4-[2-(N-methyl-N-[2-(4-phenyl-5-methylthiazolyl)]amino)ethoxy]benzyliden e)-2,4-thiazolidinedione; 5-(4-[2-(N-methyl-N-[2-(4-methyl-5-phenylthiazolyl)]amino)ethoxy]benzyl)-2, 4-thiazolidinedione; 5-(4-[2-(N-methyl-N-[2-(4-methyl-5-phenylthiazolyl)]amino)ethoxy]benzyliden e)-2,4-thiazolidinedione; 5-(4-[2-(N-methyl-N-[2-(4-methylthiazolyl)]amino)ethoxy]benzyl)-2,4-thiazol idinedione; 5-(4-[2-(N-methyl-N-[2-(4-methylthiazolyl)]amino)ethoxy]benzylidene)-2,4-th iazolidinedione; 5-[4-(2-(N-methyl-N-[2-(5-phenyloxazolyl)]amino)ethoxy)benzyl]-2,4-thiazoli dinedione; 5-(4-[2-(N-methyl-N-[2-(5-phenyloxazolyl)]amino)ethoxy]benzylidene)-2,4-thi azolidinedione; 5-(4-[2-(N-methyl-N-[2-(4,5-dimethyloxazolyl)]amino)ethoxy]benzyl)-2,4-thia zolidinedione; 5-(4-[2-(N-methyl-N-[2-(4,5-dimethyloxazolyl)]amino)-ethoxy]benzylidene)-2, 4-thiazolidinedione; 5-[4-(2-(2-pyrimidinylamino)ethoxy)benzyl]-2,4-thiazolidinedione; 5-[4-(2-(2-pyrimidinylamino)ethoxy)benzylidene]-2,4-thiazolidinedione; 5-(4-[2-(N-acetyl-N-(2-pyrimidinyl)amino)ethoxy]benzyl)-2,4-thiazolidinedio ne; 5-(4-(2-(N-(2-benzothiazolyl)-N-benzylamino)ethoxy)benzylidene)-2,4-thiazol idinedione; 5-(4-(2-(N-(2-benzothiazolyl)-N-benzylamino)ethoxy)benzyl)-2,4-thiazolidine dione; 5-(4-[3-(N-methyl-N-(2-benzoxazolyl)amino)propoxy]benzyl)-2,4-thiazolidined ione; 5-(4-[3-(N-methyl-N-(2-benzoxazolyl)amino)propoxy]benzylidene)-2,4-thiazoli dinedione; 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione; 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedi one; 5-(4-[4-(N-methyl-N-(2-benzoxazolyl)amino)butoxy]benzylidene)-2,4-thiazolid inedione; 5-(4-[4-(N-methyl-N-(2-benzoxazolyl)amino)butoxyl]-benzyl)-2,4-thiazolidine dione; 5-(4-[2-(N-(2-benzoxazolyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedione; 5-(4-[2-(N-(2-benzoxazolyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione; and 5-(4-[2-(N-isopropyl-N-(2-benzoxazolyl)amino)ethoxy]benzyl)-2,4-thiazolidin edione; or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof.